World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website http://www.wjon.org

Original Article

Volume 8, Number 4, August 2017, pages 105-109

Visceral Crisis Means Short Survival Among Patients With Luminal A Metastatic Breast Cancer: A Retrospective Cohort Study

**Table 1.** Characteristics of the Population With Advanced Breast Cancer and Visceral Crisis Disease
Baseline characteristics	35
Age at breast cancer diagnosis, median years (range)	48 ± 8.7 years
Educational level, n (%)
Illiterate	10 (28.57%)
Elementary	15 (42.85%)
Junior college	8 (22.85%)
High school	2 (5.71%)
Marital status, n (%)
Married	27 (77.14%)
Widow	8 (22.85%)
Menopausal status at the first breast cancer diagnosis, n (%)
Postmenopausal status, N (%)	28 (80%)
Pre-perimenopausal status, N (%)	7 (20%)
Insurance plan type at mBC diagnosis, n (%)	35 (100%)
Financial dependence, n (%)
Partner	31 (88.57%)
Own work	4 (11.42%)
mBC type, n (%)
De novo	35 (100%)
ECOG PS at visceral crisis, n (%)
2	31 (88.57%)
3	4 (11.42%)
Number of metastatic sites at index treatment initiation
1	19 (54.28%)
2	12 (34.28%)
3	4 (11.42%)
Sites of metastatic disease at mBC diagnosis, n (%)
Bone	15 (42.85%)
Liver	27 (77.14%)
Lung	14 (40%)
Positive ER tumor status (70-100%)	35 (100%)
Positive PgR tumor status (70-100%)	35 (100%)
Negative HER2 neu tumor status	35 (100%)
Type of index treatment for mBC, n (%)
Ovarian suppression	7 (20%)
Tamoxifene	35 (100%)
Aromatases inhibitor	35 (100%)
Fulvestrant	3 (8.5%)
Line of hormonal therapy for mBC, n (%)
First line	35 (100%)
Second line	35 (100%)
Third line	25 (100%)
Duration from initiation hormonal treatment to visceral crisis, median months (range)	18 ± 4.3 months

Table 1. Characteristics of the Population With Advanced Breast Cancer and Visceral Crisis Disease

Baseline characteristics

Age at breast cancer diagnosis, median years (range)

48 ± 8.7 years

Educational level, n (%)

Illiterate

10 (28.57%)

Elementary

15 (42.85%)

Junior college

8 (22.85%)

High school

2 (5.71%)

Marital status, n (%)

Married

27 (77.14%)

Widow

8 (22.85%)

Menopausal status at the first breast cancer diagnosis, n (%)

Postmenopausal status, N (%)

28 (80%)

Pre-perimenopausal status, N (%)

7 (20%)

Insurance plan type at mBC diagnosis, n (%)

35 (100%)

Financial dependence, n (%)

Partner

31 (88.57%)

Own work

4 (11.42%)

mBC type, n (%)

De novo

35 (100%)

ECOG PS at visceral crisis, n (%)

31 (88.57%)

4 (11.42%)

Number of metastatic sites at index treatment initiation

19 (54.28%)

12 (34.28%)

4 (11.42%)

Sites of metastatic disease at mBC diagnosis, n (%)

Bone

15 (42.85%)

Liver

27 (77.14%)

Lung

14 (40%)

Positive ER tumor status (70-100%)

35 (100%)

Positive PgR tumor status (70-100%)

35 (100%)

Negative HER2 neu tumor status

35 (100%)

Type of index treatment for mBC, n (%)

Ovarian suppression

7 (20%)

Tamoxifene

35 (100%)

Aromatases inhibitor

35 (100%)

Fulvestrant

3 (8.5%)

Line of hormonal therapy for mBC, n (%)

First line

35 (100%)

Second line

35 (100%)

Third line

25 (100%)

Duration from initiation hormonal treatment to visceral crisis, median months (range)

18 ± 4.3 months

**Table 2.** Characteristics of the Hospitalizations of Patients With Advanced Breast Cancer and Visceral Crisis Disease
Causes of death	Effect	Percentage
Progression of disease	17 patients	48.57%
Hepatic insufficiency	Nine patients	25.71%
Respiratory failure	Seven patients	20%
Septic shock	Two patients	5.71%

Table 2. Characteristics of the Hospitalizations of Patients With Advanced Breast Cancer and Visceral Crisis Disease

Causes of death

Effect

Percentage

Progression of disease

17 patients

48.57%

Hepatic insufficiency

Nine patients

25.71%

Respiratory failure

Seven patients

20%

Septic shock

Two patients

5.71%

**Table 3.** Characteristics of the Administered Treatment in Luminal Metastatic Breast Cancer With Visceral Crisis
	Effect	Percentage
Best supportive care	12	34.28%
Chemotherapy in visceral crisis disease	23	65.72%
First line of therapy	23	65.72%
Treatment modality
Epirubicine and cyclophosphamide	9	25%
Paclitaxel and bevacizumab	7	20%
Docetaxel	7	20%
Mode of administration IV	23	65.72%
Number of cycle of chemotherapy infusion
One cycle	21	91.30%
Two cycle	2	8.70%
The mean time between visceral crisis and death		4.7 ± 1.9 weeks

Table 3. Characteristics of the Administered Treatment in Luminal Metastatic Breast Cancer With Visceral Crisis

Effect

Percentage

Best supportive care

34.28%

Chemotherapy in visceral crisis disease

65.72%

First line of therapy

65.72%

Treatment modality

Epirubicine and cyclophosphamide

25%

Paclitaxel and bevacizumab

20%

Docetaxel

20%

Mode of administration IV

65.72%

Number of cycle of chemotherapy infusion

One cycle

91.30%

Two cycle

8.70%

The mean time between visceral crisis and death

4.7 ± 1.9 weeks